Logo
AZN logo
AstraZeneca PLC
AZN
204.03 (-0.47%) 0.96
Health Care
Pharmaceuticals
AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Crestor Andexxa Onglyza Symlin XIGDUO XR Atacand Atacand HCT Atacand Plus Farxiga/Forxiga Plendil Modip Splendil Munobal Flodil Tenormin Tenormine Prenormine Atenol Zestril Brilinta/Brilique Komboglyze Qtern Wainua Byetta Lokelma Seloken ZOK Toprol-XL Betaloc ZOK XIGDUO Accolate Accoleit Vanticon Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Pulmicort Turbuhaler Symbicort Turbuhaler Airsupra Bricanyl Turbuhaler Fasenra Rhinocort Tezspire Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Saphnelo Breztri Aerosphere Duaklir Genuair Pulmicort Respules and Symbicort pMDI. It also provides Beyfortus Kavigale Evusheld Fluenz/FluMist Synagis Kanuma Ultomiris Koselugo Voydeya Soliris Strensiq Nexium and other medicines. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the Americas rest of Europe Asia Africa and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.

Quality Checklist 5/8

ROIC > 10%
Debt/Equity < 1
Net Margin > 10%
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
5Y Shares Out Change < 0%
Current Ratio > 1
Quick Ratio > 1
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $316.45(B)
EV: $358.14(B)
Total Equity: $48.72(B)
Earnings date: Apr-29-2026
P/E: 30.91
Forward P/E: 19.81
P/FCF: 26.88
P/S: 5.38
P/B: 6.50
EPS: $6.6
EPS (fwd): $10.3
FCF/share: $7.6
Revenue/share: $37.9
Book value/share: $31.4
ROIC: 12.5%
ROA: 8.6%
ROE: 21.7%
Debt/Equity: 0.61
Current Ratio: 0.90
Gross margin: 81.7%
Operating margin: 22.0%
Net margin: 17.4%
Dividend/share: $3.2
Div. yield: 1.57%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.04%
Institutions: 57.09%
Other: 42.87%

Institutional ownership

1.57% Price (T.Rowe) Associa...1.19% Primecap Management Co...0.85% Bank of America Corpor...0.74% Wellington Management ...0.70% FMR, LLC0.70% Fisher Asset Managemen...0.65% Franklin Resources, In...0.47% Capital International ...0.46% Goldman Sachs Group In...0.46% Sanders Capital, LLC49.30% Others

Trading Summary

In the past year, insiders have bought $1.49(M) worth of the company's stock, and sold $53622.

Congress members have bought between $6006 - $90000 worth of the company's stock, and sold between $4004 - $60000.

Insider transactions

$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$0.002026-02$0.00
$0.002026-01$0.00
$536222025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$0.00
$0.002025-08$1.49(M)
$0.002025-07$0.00
$0.002025-06$0.00
$0.002025-05$0.00
DateSharesTotal ($)Price ($)NameTitle
Sell2025-12-1829753,622180.5Rahman (Nazneen)
Buy2025-08-149,5631,489,628155.8Sarin (Aradhana M.D.)

Congressional trading

$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$0.002026-02$0.00
$0.002026-01$0.00
$0.002025-12$16001
$0.002025-11$8001
$80012025-10$8001
$160012025-09$0.00
$0.002025-08$0.00
$0.002025-07$8001
$0.002025-06$8001
$0.002025-05$0.00
DatePoliticianPartyChamberAmount ($)
Buy2025-12-18Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Buy2025-12-08Julia LetlowRHouse$1,001 - $15,000
Buy2025-11-19Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Sell2025-10-31Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-21Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Sell2025-09-23Val T. HoyleDHouse$1,001 - $15,000
Sell2025-09-23Val T. HoyleDHouse$1,001 - $15,000
Buy2025-07-22Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-06-09Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-04-21Bruce WestermanRHouse$1,001 - $15,000
(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact